Geron (GERN) Tops Q3 EPS by 4c
More News related to GERN
- Geron (GERN) Presents Interim Data from Imetelstat at AACR-NCI-EORTC Int. Conference
- Geron Presents Interim Clinical Data on Its Telomerase Inhibitor Drug at AACR-NCI-EORTC
- Geron to Present at LCM Healthcare Conference
- Trading Outlook for StemCells Inc. Issued by InvestorSoup.com
- Geron Corp. (GERN) Reports that hESC-Derived Oligodendrocyte Progenitor Cells Reduced Cervical Spinal Cord Injury
Geron (NASDAQ: GERN) reports a Q3 loss of $0.17, 4 cents better than the analyst estimate of ($0.21). Revenue for the quarter was $494,000, which compares to the estimate of $640,000.
Related Categories
EarningsStocks Mentioned
-0.15Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
sure thing
sol on Oct 30, 2009 09:47 AMgern along with all the stem cell stocks are going to rise. Read and see how many operations are being done using your own stem cell. Doctors here are realizing stem cell works. In the past 2 weeks thers been cheeks, neck and face lift all using your own stem cell. My brother went out of the country 3 years ago and he had heart done using his own stem cell. He is 100%. The US needs to get up to date. This is a miracle. Educate because you may save your own life now.